(4S,5R)-3,4-dimethyl-5-(3-methylsulfanylphenyl)-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (4S,5R)-3,4-dimethyl-5-(3-methylsulfanylphenyl)-1,3-oxazolidin-2-one
• 化学式: C₁₂H₁₅NO₂S
• 分子量: 237.32
• InChiKey: JTWCUCRWBZRIFF-KWQFWETISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• CETP INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140221383A1

  公开（公告）日：2014-08-07

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括化合物的药物可接受盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化：在I式化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，而5元环的另一个位置具有直接连接到环或通过-CH2-连接到环的芳基，杂环，环烷基，苯并杂环或苯并环烷基取代基。
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH

  公开号：US20200222406A1

  公开（公告）日：2020-07-16

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：Dalcor Pharma UK Ltd., Leatherhead, Zug Branch

  公开号：US20210236442A1

  公开（公告）日：2021-08-05

  The invention provides compositions and methods useful for delaying occurrence of new-onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.
• US8735435B2
  申请人：——

  公开号：US8735435B2

  公开（公告）日：2014-05-27